Glaxo’s CEO Search Will Be ‘Relatively Expensive,’ Chairman Says

  • Board focused on candidates in health-care sector: Hampton
  • Company in advanced stages of recruiting one more director

Finding a replacement for Chief Executive Officer Andrew Witty, who will retire in March after nearly a decade in the job, will be “relatively expensive,” GlaxoSmithKline Plc’s chairman said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.